Revenue segments as reported by the company.

Cannabis revenue

Distribution revenue

Beverage alcohol revenue

Wellness revenue

Adult-use

Canada - Medical

International - Medical

Bulk

Hemp

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Impairment of Assets

Litigation settlement

Transaction costs

Change in fair value of contingent consideration

Restructuring costs

Other than temporary change in fair value of convertible notes receivable

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Tilray Brands

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America. The firm is focused on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extracts. It operates through the following segments: Cannabis and Hemp. The Cannabis segment consists of adult-use, medical and bulk sales of cannabis under regulated licenses and sold to retail, wholesale, pharmacy, government, and direct to patient. The Hemp segment consists of hemp seed, hemp foods, and broad spectrum hemp extract containing CBD, which are sold in an unlicensed operation and sold to retail, wholesale and direct to consumers. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Earnings data Q1 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Tilray Brands reports record revenue and optimistic outlook for 2025

Tilray Brands achieved remarkable financial performance in Q4 2024, driven by strategic acquisitions and a focus on innovation. Despite challenges like price compression, the company remains optimistic about future growth opportunities. Tilray's commitment to quality products and innovation positions it well for continued success in the market.

Tilray Brands reports record Q1 revenue growth and global expansion

Tilray Brands delivered a robust performance in Q1 2025, showcasing strong revenue growth, margin improvement, and strategic expansion across its diversified product portfolio.
While facing challenges in a competitive landscape and evolving regulatory environment, Tilray's financial strength, international growth initiatives, and focus on innovation position it well for future success.
By capitalizing on opportunities in wellness products, expanding into new beverage categories, and leveraging strategic partnerships, Tilray is poised for continued growth and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. The Cannabis Business segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution Business segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage Alcohol Business segment refers to the production, marketing, and sale of beverages. The Wellness Business segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Aurora Cannabis

Canopy Growth

Curaleaf Holdings, Inc.

Green Thumb Industries Inc.

Last month, the Department of Health and Human Services suggested easing regulations on marijuana use. The Drug Enforcement Agency has final say on that -- but its boss, President Joe Biden, now says he supports medical marijuana legalization.

Why Marijuana Stocks Keep Growing Higher Tuesday

Cronos Group

OrganiGram Holdings Inc.

Trulieve Cannabis Corp.

Cannabis stocks continued to move higher following the Labor Day long weekend after the U.S. Department of Health and Human Services (HHS) last week recommended reclassifying marijuana as a lower-risk drug.

Cannabis stock rally continues on marijuana rescheduling hopes

Tilray (NASDAQ: TLRY ) stock is climbing higher on Tuesday as investors continue to hold out hope for the decriminalization of marijuana. The excitement around decriminalization comes after a letter was sent to the DEA seeking to reduce it from a Schedule I to Schedule III drug.

Why Is Tilray (TLRY) Stock Up 7% Today?

Anheuser-Busch InBev

Tilray agreed to pay AB InBev $85 million in cash to acquire eight leading beer brands. The purchase will triple Tilray's beer business, making it the fifth-largest craft brewer in the U.S. It's a smart move to diversify as Tilray's core cannabis segment languishes in the near term.

Tilray Just Acquired 8 Big Beer Brands From Anheuser-Busch. Is the Stock About to Pop?

In a previous article, I discussed Tilray's acquisition of Truss Beverage a company that makes cannabis infused beverages. Cannabis producers like Tilray (NASDAQ: TLRY ) often raise investor caution due to their historical volatility.

Tilray's Cannabis Beverage Move: Is It Time to Buy, Hold or Sell?

Cannabis stocks are on track to finish the week higher boosted by the news that the U.S. Department of Health and Human Services (HHS) has recommended reclassifying marijuana as a lower-risk drug.

Cannabis stocks set to end week on a high following marijuana rescheduling recommendation

Innovative Industrial Properties

Amplify Alternative Harvest ETF

Roundhill Cannabis ETF

When it comes to marijuana, a significant disconnect exists between the US government and the American people. Stock Strategist Andrew Rocco explains why the worst may be over for marijuana investors.

Time to Get High on Pot Stocks? (3 Catalysts)

Canopy Growth (CGC), Tilray (TLRY) and Cronos (CRON) shoot up on news that the DEA is considering recommendations for low-risk reclassification of marijuana.

3 Cannabis Stocks Soaring on HHS' Recommendation to DEA

Brinker International

Groupon

Recently released macro economic data is indicating that the United States economy is heading for a “soft landing.” Specifically, according to the Department of Labor's  Job Openings and Labor Turnover Survey (JOLTS) for July, “2.3%  of nonfarm payroll workers quit their jobs” last month, versus the high of 35 during the “Great Resignation.

3 Beaten-Down Stocks Due for a Massive Short Squeeze

The recommendation is part of a larger marijuana reform plan announced by the Biden Administration last year.

Cannabis Stocks Surge After HHS Recommends Classifying Marijuana As Lower-Risk Drug

If marijuana is downgraded to a Schedule III drug, it could be a huge boost to a struggling industry.

U.S. health officials want to loosen marijuana restrictions. Here's what it means

Cannabis stocks are celebrating this morning after the U.S. Department of Health and Human Services recommended in a letter to the Drug Enforcement Administration that Marijuana be reclassified as a Schedule III drug.

Why are cannabis stocks trading significantly up on Thursday?

AdvisorShares Pure US Cannabis ETF

Global X Cannabis ETF

The move by the Drug Enforcement Administration to review the Schedule I classification for cannabis sparked a wave of speculation and mostly positive comments from Wall Street on Thursday, but many questions remain.

HHS recommendation to reschedule cannabis keeps pot stocks hot, but questions remain

Bright Green Corp

SNDL Inc.

The cannabis sector is one of the most challenging sectors in the market, leading to speculative cannabis stocks. If you've been following it for the last few years, you know the roller coaster ride investors have ridden.

High Risk, High Reward: 3 Cannabis Stocks for the Bold Trader

Tilray (NASDAQ: TLRY ), a Canada-based cannabis company, is trending, and TLRY stock is up about 5% in early trading after jumping nearly 11% yesterday. The rally was sparked by a report that the U.S. Department of Health and Human Services (HHS) has recommended that the federal government fundamentally change its official view of cannabis.

TLRY Stock Alert: Watch This Upside Catalyst for Tilray Closely

Cannabis stocks are up on Thursday as investors in the market react to news marijuana may be downgraded from a Schedule I drug. According to insiders, a member of the Department of Health and Human Services is seeking a drop in the drug from Schedule I to Schedule III.

Why Are Cannabis Stocks TLRY, ACB, CGC, CURLF Up Today?

The U.S. government appears finally to be ready to review its categorization of marijuana as a dangerous drug, reviving hope among investors and marijuana producers for an industry that took off like a rocket five years ago before sinking like a rock less than two years later.

Will a Change to US Marijuana Policy Save Any of the Weed Companies?

Assistant Secretary for Health Rachel Levine reportedly requested in a letter to DEA Administrator Anne Milgram that marijuana be downgraded to a schedule III substance.

Pot stocks rally after health officials ask DEA to reclassify marijuana as lower-risk drug

The Drug Enforcement Agency received an official recommendation to downgrade marijuana.  Currently, pot is classified as a Schedule I drug, on par with heroin.

Pot stocks jump as federal agency reportedly seeks to downgrade cannabis from the hard-drug category

President Joe Biden is asking the DEA to reclassify marijuana as a Schedule III drug. The DEA has the authority to reschedule a drug under the Controlled Substances Act.

Why Tilray Stock Surged Today

That move could potentially expand the market for cannabis, sending shares of Canopy Growth, Tilray Brands and Cronos Group higher.

HHS calls for easing restrictions on marijuana, sending cannabis stocks higher

Ardelyx

EVgo

There's a certain allure in the world of penny stocks. For savvy investors, the promise of top penny stock picks is too enticing to resist, especially when you can scoop up several shares with a $100 bill.

The 3 Most Promising Penny Stocks to Own Now

The U.S. Department of Health and Human Services is recommending to the U.S. Drug Enforcement Administration that cannabis should be reclassified as a Schedule III controlled substance under U.S. law from Schedule I now, according to a report by Bloomberg. Cannabis stocks are rallying, with the AdviserShares Pure US Cannabis ETF MSOS, +18.76% up by nearly 33%, and the ETFMG Alternative Harvest ETF MJ, +10.27% up by 19.5%.

U.S. Dept. of Health and Human Services recommends re-scheduling cannabis, as stocks in the sector rally

Tilray has a trio of hurdles to clear if it wants to delight investors. Its alcohol segment's profitability and its cannabis sales will be key to watch.

3 Key Tests for Tilray Stock in Fall 2023

The New Hand-Crafted RIFF Diamond Infused Pre-rolls and Blunts Are Now Available in Ontario PURE ‘DIAMONDS COLLECTION' IS ‘A CUT ABOVE'    TORONTO, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis and consumer packaged goods company, today debuts its new ‘Diamonds Collection' by its Premium cannabis lifestyle brand RIFF . Introducing its new Diamond Infused Pre-rolls, including Melonaide and Purple Punch OG strains, and '26 Delta Diamond Infused Blunts featuring Blue CKS featuring Girl Scout Cookies (GSC) lineage and Blueberry Kush, both produced with small-batch, hand-crafted whole flower boosted by THCA diamonds and premium full spectrum resin.

News for Tilray Brands Stock (TLRY)